Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 9/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 9/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 7/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.51 |
| ▸ | USP2 | O75604 | 2/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 8/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 7/20 | 0.47 |
| ▸ | TSHR | P16473 | 6/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.46 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12254227 | 0.85 | CYP2C9 (0.54) | CYP2C9CYP1A2CYP2D6ALDH1A1USP2 | |
| SCHEMBL3940936 | 0.81 | HPGD (0.45) | ALDH1A1USP2HPGD | |
| SCHEMBL24711544 | 0.81 | HPGD (0.45) | ALDH1A1USP2HPGD | |
| SCHEMBL24095376 | 0.81 | HPGD (0.45) | ALDH1A1USP2HPGD | |
| SCHEMBL29891860 | 0.79 | CYP1A2 (0.65) | CYP2C9CYP1A2CYP2D6ALDH1A1USP2 | |
| SCHEMBL9718108 | 0.79 | CYP2C9 (0.49) | CYP2C9CYP1A2CYP2D6ALDH1A1USP2 | |
| SCHEMBL3947734 | 0.79 | VNN1 (0.37) | CYP2C9CYP1A2CYP2D6ALDH1A1USP2 | |
| SCHEMBL4550437 | 0.79 | CYP3A4 (0.43) | CYP1A2CYP2D6ALDH1A1USP2CYP3A4 | |
| SCHEMBL30728778 | 0.78 | POLB (0.48) | CYP2C9CYP1A2CYP2D6ALDH1A1USP2 | |
| SCHEMBL1983220 | 0.78 | CYP2C9 (0.51) | CYP2C9CYP1A2CYP2D6ALDH1A1USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110039838-A1 | PYRROLOTRIAZINE COMPOUNDS AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2011-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110039838-A1 | PYRROLOTRIAZINE COMPOUNDS AS KINASE INHIBITORS | ERBB2, ERBB4, ERBB3 | CYP2C9 3796/4885CYP1A2 2536/4885CYP2D6 2028/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.